An Engineered Hybrid Protein from Allergens Shows Hypoallergenicity.

The house dust mite (HDM) is an important risk factor for asthma and rhinitis. Allergen specific immunotherapy that is based on recombinant proteins has been proposed for the safer and more efficient treatment of allergic diseases. The aim of this study was to design and obtain a hybrid protein (DPx4) containing antigenic regions of allergens Der p 1， Der p 2， Der p 7， and Der p 10 from this mite. DPx4 was produced in and its folding was determined by circular dichroism. Non-denaturing dot-blot， ELISA， basophil activation test， dot blot with monoclonal antibodies， ELISA inhibition， and cysteine protease activity assays were performed. Mice that were immunized with DPx4 were also analyzed. We found that DPx4 had no cysteine protease activity and it showed significantly lower IgE reactivity than Der p 1， Der p 2， and extract. DPx4 induced lower basophil activation than Der p 2 and the allergen extract. Immunized mice produced IgG antibodies that inhibited the binding of allergic patient's IgE to the allergen extract and induced comparatively higher levels of IL-10 than the extract in peripheral blood mononuclear cells (PBMC) culture. These results suggest that DPx4 has immunological properties that are useful for the development of a mite allergy vaccine.